LGT Capital Partners LTD. Has $18.65 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• LGT Capital Partners LTD. increased its position in IQVIA Holdings Inc. by 40.9%, acquiring a total of 105,800 shares worth approximately $18.7 million.
• Insider transactions showed significant selling as Eric Sherbet and Keriann Cherofsky decreased their holdings by 17.59% and 15.87%, respectively, following sales on July 23rd.
• IQVIA's stock price recently dropped by 1.8%, with shares opening at $182.44, while the company reported a 5.3% revenue increase year-over-year, generating $4.02 billion in the last quarter.

LGT Capital Partners LTD. lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 40.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 105,800 shares of the medical research company's stock after buying an additional 30,700 shares during the quarter. LGT Capital Partners LTD. owned approximately 0.06% of IQVIA worth $18,653,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Sowell Financial Services LLC acquired a new stake in shares of IQVIA during the 1st quarter worth $305,000. Mather Group LLC. grew its stake in IQVIA by 83.5% during the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares in the last quarter. Park Avenue Securities LLC raised its holdings in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after acquiring an additional 1,562 shares in the last quarter. Private Advisor Group LLC grew its stake in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after purchasing an additional 566 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of IQVIA by 34.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after acquiring an additional 3,398 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on IQV shares. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Robert W. Baird upped their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Finally, HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and decreased their price target for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Price Performance

Shares of IQV traded down $0.23 during trading hours on Thursday, hitting $177.27. The stock had a trading volume of 179,461 shares, compared to its average volume of 2,016,742. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company's fifty day moving average is $163.90 and its two-hundred day moving average is $169.69. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $30.14 billion, a price-to-earnings ratio of 25.64, a P/E/G ratio of 2.02 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the firm earned $2.64 EPS. The company's revenue was up 5.3% on a year-over-year basis. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.